Hyaluronic acid synthesis pathway

The hyaluronic acid synthesis pathway comprises a series of enzymatic reactions in which glucose is converted to UDP-glucuronic acid and UDP-N-acetylglucosamine, which are then polymerized by hyaluronan synthases (HAS1, HAS2, HAS3) to form hyaluronic acid (HA).[1][2][3] This pathway is critical for the production of HA, a major glycosaminoglycan component of the extracellular matrix involved in cell migration, proliferation, and tissue hydration.[2][4] The HAS enzymes are integral membrane proteins that assemble HA at the plasma membrane, directly secreting it into the extracellular space.[2][3] The activity of this pathway is tightly regulated at both the metabolic (precursor supply) and transcriptional/post-translational (enzyme expression/modification) levels.[3][4] Dysregulation of HA synthesis is implicated in various diseases, including cancer, inflammation, and fibrosis. While individual enzymes or steps of the pathway (such as HAS2) may be considered therapeutic targets, the "hyaluronic acid synthesis pathway" itself is not a discrete drug target or molecule, thus it is not appropriate as a single therapeutic target entry.[4][6]

Other names

Hyaluronan synthesis pathwayHA synthesis pathway

Inhibition of hyaluronan synthase (HAS) expression or function Depletion of UDP-glucuronic acid precursor